ClinicalTrials.Veeva

Menu

Impact of TMAO Serum Levels on Hyperemic IMR in STEMI Patients (TAMIR)

L

Lithuanian University of Health Sciences

Status

Completed

Conditions

STEMI - ST Elevation Myocardial Infarction
Microvascular Coronary Artery Disease

Treatments

Procedure: pressure-temperature sensor guidewire-based measurement

Study type

Observational

Funder types

Other

Identifiers

NCT05406297
LUHSKC-176

Details and patient eligibility

About

Trimethylamine N-oxide (TMAO) is a gut microbiota-dependent metabolite of dietary choline, L-carnitine, and phosphatidylcholine-rich foods. On the basis of experimental studies and patients with prevalent disease, elevated plasma TMAO may increase risk of atherosclerotic cardiovascular disease (ASCVD). However, to our knowledge, no data is available on its impact on coronary microcirculation.

Enrollment

400 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patient diagnosed with STEMI
  2. Availability of non- left anterior descending artery (LAD) non culprit lesion, which is planned for a staged Percutaneous coronary intervention (PCI)

Exclusion criteria

  1. patient undergoing cardiopulmonary resuscitation;
  2. patients with a history of old myocardial infarction or history of coronary artery bypass grafting (CABG) or Percutaneous coronary intervention PCI
  3. Patients with signs of chronic infection, prolong usage of corticosteroids or compromised immune system
  4. patients had thrombolysis before primary Percutaneous coronary intervention (pPCI)
  5. had contraindication of adenosine triphosphate (ATP);
  6. had a history of liver or renal function dysfunction
  7. Patients with dementia
  8. Patients being referred to CABG after primary PCI
  9. unable to provide informed consent;
  10. had pregnancy or life span < 1 year.
  11. Presence of sever structural valvular heart disease
  12. Presence of significant left main disease
  13. Unability to measure the index of microcirculatory resistance due to (death or retraction from the study ...etc)
  14. Inability to perform successful PCI

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems